| Name | ADAS |
|---|---|
| Synonyms | ADAP S; ADAS; ADHAPS; ADPS; AGPS; ALDHPSY; Aging associated protein 5; Alkyl DHAP synthase… |
| Name | trichlorfon |
|---|---|
| CAS |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 10867446 | Farlow MR, Cyrus PA: Metrifonate therapy in Alzheimer's disease: a pooled analysis of four randomized, double-blind, placebo-controlled trials. Dement Geriatr Cogn Disord. 2000 Jul-Aug;11(4):202-11. Metrifonate 60/80 mg significantly improved the cognitive abilities [AD Assessment Scale - Cognitive Subscale (ADAS-Cog), p = 0.0001; Mini Mental State Examination (MMSE), p = 0.0001], psychiatric and behavioral disturbances (Neuropsychiatric Inventory, p = 0.039; ADAS - Noncognitive Subscale, p = 0.0001), performance of instrumental and basic activities of daily living (Disability Assessment for Dementia, p = 0.0002) and global status (Clinician's Interview-Based Impression of Change with Caregiver Input, p = 0.0001) of AD patients when compared with placebo. |
2(0,0,0,2) | Details |
| 11234910 | Mega MS, Cummings JL, O'Connor SM, Dinov ID, Reback E, Felix J, Masterman DL, Phelps ME, Small GW, Toga AW: Cognitive and metabolic responses to metrifonate therapy in Alzheimer disease. Neuropsychiatry Neuropsychol Behav Neurol. 2001 Jan;14(1):63-8. Clinical evaluations included the cognitive portion of the Alzheimer's Disease Assessment Scale (ADAS-cog), the Mini-Mental State Examination (MMSE), and the Neuropsychiatric Inventory. |
2(0,0,0,2) | Details |
| 10090427 | Jann MW, Cyrus PA, Eisner LS, Margolin DI, Griffin T, Gulanski B: Efficacy and safety of a loading-dose regimen versus a no-loading-dose regimen of metrifonate in the symptomatic treatment of Alzheimer's disease: a randomized, double-masked, placebo-controlled trial. Clin Ther. 1999 Jan;21(1):88-102. The primary measure of efficacy was the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog); secondary measures of efficacy included the Mini-Mental State Examination (MMSE), the Clinician's Interview Based Impression of Change with Caregiver Input (CIBIC-Plus), the Clinician's Interview Based Impression of Severity with Caregiver Input (CIBIS-Plus), and the ADAS-Noncognitive Subscale (ADAS-Noncog). |
2(0,0,0,2) | Details |
| 11789125 | Schreiter Gasser U, Gasser T: [A comparison of cholinesterase inhibitors and ginkgo extract in treatment of Alzheimer dementia]. Fortschr Med Orig. 2001 Nov 29;119(3-4):135-8. METHOD: Analysis of the effect on cognition with the aid of the ADAS-cog.scale, placebo-adjusted, within six months; statistical evaluation of the effect using the confidence interval for the potential mean improvement. |
1(0,0,0,1) | Details |
| 10599773 | Farlow MR, Cyrus PA, Nadel A, Lahiri DK, Brashear A, Gulanski B: Metrifonate treatment of AD: influence of APOE genotype. Neurology. 1999 Dec 10;53(9):2010-6. RESULTS: Metrifonate clearly improved the cognitive performance of the AD patients when compared with placebo (Alzheimer's Disease Assessment Scale-Cognitive Subscale [ADAS-Cog], p = 0.0001). |
1(0,0,0,1) | Details |
| 9585171 | Cutler NR, Jhee SS, Cyrus P, Bieber F, TanPiengco P, Sramek JJ, Gulanski B: Safety and tolerability of metrifonate in patients with Alzheimer's disease: results of a maximum tolerated dose study. Life Sci. 1998;62(16):1433-41. A pilot study, and Phase I and Phase II studies of metrifonate in Alzheimer's disease (AD) patients conducted prior to the current study showed benign, dose-dependent adverse event profiles consisting primarily of gastrointestinal events, optimal daily dosing with a loading phase (in the absence of a loading dose phase, 6-8 weeks were required to attain steady-state AChE inhibition levels), and an improvement in Alzheimer's Disease Assessment Scale (ADAS) scores. |
1(0,0,0,1) | Details |
| 8876775 | Becker RE, Colliver JA, Markwell SJ, Moriearty PL, Unni LK, Vicari S: Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease. Alzheimer Dis Assoc Disord. 1996 Fall;10(3):124-31. The Alzheimer Disease Assessment Scale cognitive subscale score (ADAS-C) served as the primary outcome measure. |
3(0,0,0,3) | Details |
| 10556869 | Dubois B, McKeith I, Orgogozo JM, Collins O, Meulien D: A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study. Int J Geriatr Psychiatry. 1999 Nov;14(11):973-82. Four main clinical domains of AD were assessed: cognition (ADAS-cog and MMSE), psychiatric and behavioural symptoms (ADAS-noncog and NPI), instrumental and basic activities of daily living (DAD) and global functioning (CIBIC-plus, CIBIS-plus and GDS). |
3(0,0,0,3) | Details |
| 9595967 | Morris JC, Cyrus PA, Orazem J, Mas J, Bieber F, Ruzicka BB, Gulanski B: Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology. 1998 May;50(5):1222-30. Primary efficacy variables were the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) and the Clinician's Interview-Based Impression of Change with Caregiver Input (CIBIC-plus). |
3(0,0,0,3) | Details |
| 10362441 | Raskind MA, Cyrus PA, Ruzicka BB, Gulanski BI: The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. J Clin Psychiatry. 1999 May;60(5):318-25. Cognitive performance was analyzed using the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) and the MMSE. |
3(0,0,0,3) | Details |
| 9595966 | Cummings JL, Cyrus PA, Bieber F, Mas J, Orazem J, Gulanski B: Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Neurology. 1998 May;50(5):1214-21. Metrifonate significantly improved cognitive ability, as assessed by the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), and enhanced global function, as assessed the Clinicians's Interview-Based Impression of Change with Caregiver Input (CIBIC-Plus). |
2(0,0,0,2) | Details |